INTRODUCTION
Hyperbilirubinemia is commonly present in the newborn period and becomes visible in approximately 50% of infants.
Jaundiced infants are usually treated with phototherapy, and exchange transfusion is now a rare event in hyperbilirubinemic infants without hemolytic disease. Treatment of neonatal hyperbilirubinemia is usually based on the measurement of total serum bilirubin levels. 1, 2 However, several different approaches to establish criteria for treatment of hyperbilirubinemia in the newborn infant have been suggested, as summarized in Table 1 .
TREATMENT CRITERIA BASED ON TOTAL SERUM BILIRUBIN CONCENTRATIONS
As reviewed by Maisels 3 there is a definite association between the concentration of unconjugated bilirubin in the serum and the occurrence of kernicterus, as well as the developmental outcome in infants. Most studies have found a significant risk for development of kernicterus in infants when serum bilirubin levels exceed 340 mol/l, and this relationship seems to be more prominent in term infants. The commonly used criteria for treatment of neonatal jaundice are, therefore, based on measurements of total serum bilirubin only. Recent studies suggest that noninvasive, transcutaneous measurements of serum bilirubin are also clinically useful for estimation of serum bilirubin levels, 4 even during phototherapy. 5 Term and Near-Term Infants Most treatment schedules recommend phototherapy when serum bilirubin levels exceeds 250 mol/l in infants below 2.500 g and 300 to 350 mol/l in term infants during the first 5 days of life. 6, 7 Higher bilirubin levels will often result in exchange transfusion. Furthermore, phototherapy is usually started at lower bilirubin levels at an earlier postnatal age. An international survey conducted in 1993 of 108 newborn nurseries 8 indicated a median maximum bilirubin level of 300 mol/l for start of phototherapy at day 5, compared to 175 mol on day 1 and 225 mol/l on day 3. Exchange transfusion was considered at bilirubin levels of 400 to 450 mol/l. However, wide variations were found between nurseries.
Low Birth Weight and Very Low Birth Weight Infants
Although the treatment criteria for hyperbilirubinemia in the term and near-term infant largely are based on the experience from the treatment of infants with Rh disease, the management of hyperbilirubinemia in low birth weight infants Treatment of neonatal hyperbilirubinemia is usually based on the measurements of total serum bilirubin levels. Based on empirical data, it is generally recommended to start phototherapy at lower levels in low birth weight and very low birth weight infants than in term infants, but no general agreement exists on exact limits. Treatment criteria in preterm infants do not, however, have the same empirical backing as in term infants. The very low and extremely low birth weight infants are more susceptible to bilirubin toxicity. However, bilirubin may function as an antioxidant and enzyme inducer in these infants. Several other different approaches to establish treatment criteria have also been suggested, and a summary of these are presented and discussed. With the exception of measurement of unbound bilirubin, very few of these approaches have been validated in routine clinical settings. However, unbound bilirubin is at present mainly used also as a parameter to be evaluated in relation to total bilirubin values. The present treatment criteria result in a considerable overtreatment particularly of term infants. However, with a more relaxed attitude toward neonatal hyperbilirubinemia by health care professionals, kernicterus is again reported in term infants. Because the basic mechanisms of bilirubin toxicity as well as the relative significance of the maximum serum bilirubin level compared to the duration of hyperbilirubinemia are not known, individual assessment of a newborn infant's tolerance for hyperbilirubinemia is difficult. Major changes in the empirically developed criteria for treatment of hyperbilirubinemia in the newborn are therefore not justified in the near future. For term infants, the search for validated criteria for follow -up of jaundiced infants after discharge are therefore more important than revision of existing criteria for phototherapy. Journal of Perinatology 2001; 21:S88 -S92.
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lacks this empirical basis. Several physiological differences from term infants indicate an increased risk for bilirubin toxicity in the immature newborn. 9 It is therefore generally recommended to treat hyperbilirubinemia at lower levels in low birth weight infants than in term infants. However, while the possible positive effects of bilirubin as an antioxidant and enzyme inducer may be of little importance in the term infant, this might be of considerable significance in the premature infant. In a recent review article, 9 it was recommended to start phototherapy at 140 mol/l in infants below 750 g, at 170 mol/l in infants below 1000 g, and at 200 mol/l in infants below 1500 g. Exchange transfusion should be considered at a level of 200 to 250 mol/l in the smallest infants and at 300 to 340 mol/l in the largest infants. These recommendations correspond fairly well with the criteria reported in the international survey of 108 neonatal units worldwide. 8 
TREATMENT CRITERIA BASED ON UNBOUND BILIRUBIN CONCENTRATIONS
The toxic effects of bilirubin are probably not related to the serum bilirubin level as such, but to the fraction of unbound bilirubin. 10 Because several factors can increase the level of unbound bilirubin by reducing the binding capacity of the albumin molecule, 10 the correlation between the level of unbound and total bilirubin is not close. Reduced binding can be seen in newborns with low albumin levels such as premature infants and sick infants. Also, several substances (drugs, fatty acids) can displace bilirubin from the albumin molecule. Unbound bilirubin levels, therefore, more directly reflect the toxic potential of the hyperbilirubinemia in jaundiced newborns. Some studies suggest that levels of unbound bilirubin are better predictors of bilirubin encephalopathy than total bilirubin concentrations.
11 However, such findings need to be confirmed in more studies, particularly in the very low birth weight infant. 12 Although several of these tests are interesting tools for in vitro studies of bilirubin toxicity, none of these tests have been validated properly in controlled clinical trials.
TREATMENT CRITERIA BASED ON ALBUMIN BINDING CAPACITY
Bilirubin bound to the primary binding site on the albumin molecule is probably not toxic. Therefore, it has been suggested to use tests for estimating the albumin binding capacity for bilirubin in the evaluation of treatment indications for neonatal jaundice. Among these tests are bilirubin titration tests, dye-binding tests, selective binding of tracer ligands, and tests for determination of the amount of loosely bound bilirubin.
TREATMENT CRITERIA BASED ON BILIRUBIN PRODUCTION RATES
Bilirubin production rates measured as the rate of rise in serum bilirubin levels have always been included in the criteria for treatment of hyperbilirubinemia, particularly in hemolytic diseases. 2, 4 A high production rate could result in a more rapid transfer of bilirubin into the tissues. A rise in serum bilirubin, during the first 24 hours, of 5 to 10 mol/l per hour has been used as a criterion for start of phototherapy. Values above this usually indicate the need for exchange transfusion. However, the rate of increase in serum bilirubin does not only reflect bilirubin production, but disposition and distribution as well. Bilirubin production rates can now be measured by the production of carbon monoxide (CO), which is formed in equimolar concentrations. CO binds to the hemoglobin of the circulating erythrocytes and can be measured as carboxyhemoglobin (COHb) in the blood or exhaled CO in the breath. 13 By measuring exhaled CO in the newborn, it is, therefore, also possible to accurately measure bilirubin production. It has recently been demonstrated that such measurements may be of importance in identifying infants at risk for the development of bilirubin toxicity. Bilirubin production rates resulting in end-tidal CO concentrations above 2.0 ppm seems to indicate an increased bilirubin production and risk for development of significant hyperbilirubinemia. 14 In the future, bilirubin production rates might be a very important parameter in the evaluation of treatment criteria.
TREATMENT CRITERIA BASED ON NEUROPHYSIOLOGIC MEASUREMENTS
In infants with hyperbilirubinemia significant effects can be seen on neurophysiologic measurements, such as brainstem auditory evoked response (BAER), visual evoked potentials (VEP), and somatosensory evoked potentials (SEP). 15 Such measurements have, however, been of little practical value in a routine clinical setting; neither has the use of cry analysis. 16 
TREATMENT CRITERIA BASED ON CLINICAL CONDITIONS
It has been a general observation that sick infants have a reduced tolerance for bilirubin toxicity. Also, infants with hemolytic disease will show signs of bilirubin toxicity at lower bilirubin levels than infants without hemolysis. This may be explained by an increase in the levels of unbound bilirubin. Other factors also play a role, such as the integrity of the blood-brain barrier. 10 Furthermore, acidosis, asphyxia, and hypothermia have been suggested as risk factors for bilirubin toxicity and a more aggressive treatment has been advocated in such clinical conditions. Premature infants and infants with hemolytic disease are therefore usually treated at lower bilirubin levels. It is usually recommended to reduce treatment criteria based on total bilirubin levels with 50 mol/l in such cases. Some authors have tried to combine several such clinical risk parameters into nomograms for treatment criteria. 17 
PROPHYLACTIC TREATMENT OF HYPERBILIRUBINEMIA
The duration of hyperbilirubinemia, the so-called area under the curve, and not only the maximum bilirubin level reached might be of significance for development of bilirubin toxicity. 18 Therefore, prophylactic treatment has been recommended for infants with prenatally diagnosed severe hemolytic disease and in extremely low birth weight infants. In some cases treatment has started even before delivery by giving the mother phenobarbital to induce glucuronyl transferase activity in the liver. The introduction of tin (SN)-mesoporphyrin 19 as well as peroral bilirubin oxidase 19 for the treatment of neonatal jaundice could possibly establish prophylactic treatment as a major approach to infants with neonatal jaundice in the future. If so, treatment criteria could be more related to group diagnosis (prematurity, hemolytic disease) rather than to postnatal measured parameters of bilirubin metabolism in the individual patient.
It has recently been demonstrated that the plasma membrane efflux pump P-glycoprotein plays a central role in protecting the brain from injury by neurotoxins such as bilirubin. 20 It is possible that this research can result in other pharmacological strategies to prevent bilirubin toxicity in the newborn.
DISCUSSION
Hyperbilirubinemia is still one of the most frequent complications in the newborn period, particularly in the premature infants. It has been estimated that between 5 and 10% of all newborn infants are treated for hyperbilirubinemia. There is therefore a definite need for exact criteria for such treatment and follow-up.
With the present treatment criteria (based on serum bilirubin levels) kernicterus was rarely seen in newborn infants. However, these criteria also result in a considerable overtreatment of infants, particularly term infants. A kinder and gentler approach, as suggested by Newman and Maisels 21 would therefore be welcome. However, as shown in Table 2 , our present knowledge of bilirubin metabolism and toxicity leaves many questions unsolved, complicating the process of a major revision of the empirically based treatment criteria. It is, therefore, not surprising that with a more relaxed attitude toward neonatal hyperbilirubinemia by health care professionals, kernicterus is again reported in term infants. 7 A shift to a kinder and gentler diagnostic and therapeutic approach has, therefore, the possibility of increasing the risk of bilirubin toxicity for a small number of patients for the benefit of the many who would not be unnecessarily treated. As a comparison, increasing the speed limit on the road results in fewer drivers being ticketed for speeding, but it does not reduce the risks of speeding. Accidents may therefore increase because the message to the drivers is that speed is not important. As with hyperbilirubinemia, it is also difficult to identify which driver (patient) will not handle the increased speed (increased bilirubin levels). As with traffic accidents, bilirubin toxicity not only causes fatalities or serious damage (cerebral palsy), but also minor injuries, from which the infant may or may not recover completely. Bilirubin effects on hearing may be such a minor ''traffic'' injury. Treatment criteria and follow-up criteria (speed limits) must, therefore, be set with wide safety margins.
Treatment criteria must also take into account the efficacy of the treatment given. Significant differences in effective irradiance have been reported among the different phototherapy units in use, with special blue lamps being the most effective, also when measured as decline in serum bilirubin concentrations over time. Recently, phototherapy units based on light-emitting diodes with very high irradiance have also been shown to give a more rapid decrease in bilirubin levels both in vitro and in vivo, compared to standard phototherapy units. 22 A nursery using only highly effective phototherapy units could probably accept higher bilirubin levels before treatment is started, because the more rapid decline in bilirubin levels would reduce the total exposure to bilirubin (area under the curve).
A kinder and gentler approach must therefore be followed by an increased effort in identifying the infants at risk. A more case-specific diagnosis with measurements of unbound bilirubin, bilirubin production rates, and nomograms taking into account important biochemical and clinical parameters might be an approach, but probably not useful in a clinical setting with early discharge. The suggestion of guidelines for follow-up based on the percentile of hour-specific bilirubin 7 could be a useful approach in identifying the infants who need to be followed more closely. However, because neither the basic mechanisms behind the development of bilirubin toxicity nor the relative significance of the maximum serum bilirubin level compared to the duration of hyperbilirubinemia is known, even this approach will not justify significant changes in criteria for treatment.
